BACKGROUND: Bilirubin, a natural product of heme catabolism by heme oxygenases, was considered a toxic waste product until 1987, when its antioxidant potential was recognized. On the basis of observations that oxidative stress is a potent trigger in vascular proliferative responses, that heme oxygenase-1 is antiatherogenic, and that several studies now show that individuals with high-normal or supranormal levels of plasma bilirubin have a lesser incidence of atherosclerosis-related diseases, we hypothesized that bilirubin would have salutary effects on preventing intimal hyperplasia after balloon injury. METHODS AND RESULTS: We found less balloon injury-induced neointima formation in hyperbilirubinemic Gunn rats and in wild-type rats treated with biliverdin, the precursor of bilirubin, than in controls. In vitro, bilirubin and biliverdin inhibited serum-driven smooth muscle cell cycle progression at the G1 phase via inhibition of the mitogen-activated protein kinase signal transduction pathways and inhibition of phosphorylation of the retinoblastoma tumor suppressor protein. CONCLUSIONS: Bilirubin and biliverdin might be potential therapeutics in vascular proliferative disorders.
BACKGROUND:Bilirubin, a natural product of heme catabolism by heme oxygenases, was considered a toxic waste product until 1987, when its antioxidant potential was recognized. On the basis of observations that oxidative stress is a potent trigger in vascular proliferative responses, that heme oxygenase-1 is antiatherogenic, and that several studies now show that individuals with high-normal or supranormal levels of plasma bilirubin have a lesser incidence of atherosclerosis-related diseases, we hypothesized that bilirubin would have salutary effects on preventing intimal hyperplasia after balloon injury. METHODS AND RESULTS: We found less balloon injury-induced neointima formation in hyperbilirubinemicGunn rats and in wild-type rats treated with biliverdin, the precursor of bilirubin, than in controls. In vitro, bilirubin and biliverdin inhibited serum-driven smooth muscle cell cycle progression at the G1 phase via inhibition of the mitogen-activated protein kinase signal transduction pathways and inhibition of phosphorylation of the retinoblastoma tumor suppressor protein. CONCLUSIONS:Bilirubin and biliverdin might be potential therapeutics in vascular proliferative disorders.
Authors: Angelo A Chora; Paulo Fontoura; Andreia Cunha; Teresa F Pais; Sílvia Cardoso; Peggy P Ho; Lowen Y Lee; Raymond A Sobel; Lawrence Steinman; Miguel P Soares Journal: J Clin Invest Date: 2007-01-25 Impact factor: 14.808
Authors: Arno Lingenhel; Barbara Kollerits; Johannes P Schwaiger; Steven C Hunt; Richard Gress; Paul N Hopkins; Veit Schoenborn; Iris M Heid; Florian Kronenberg Journal: Exp Gerontol Date: 2008-08-26 Impact factor: 4.032
Authors: Bhavisha A Bakrania; Frank T Spradley; Simon C Satchell; David E Stec; John M Rimoldi; Rama S V Gadepalli; Joey P Granger Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-12-06 Impact factor: 3.619
Authors: H Yasuda; S Okinaga; M Yamaya; T Ohrui; M Higuchi; M Shinkawa; S Itabashi; K Nakayama; M Asada; A Kikuchi; S Shibahara; H Sasaki Journal: J Med Genet Date: 2006-04 Impact factor: 6.318
Authors: K H Chan; R L O'Connell; D R Sullivan; L S Hoffmann; K Rajamani; M Whiting; M W Donoghoe; M Vanhala; A Hamer; B Yu; R Stocker; M K C Ng; A C Keech Journal: Diabetologia Date: 2013-01-17 Impact factor: 10.122